Advanced

Do we need PSA and early detection of prostate cancer?

Abrahamsson, Per-Anders LU and Tinzi, Martina (2008) In European Urology. Supplement 7(5). p.393-395
Abstract
The limitations of PSA as a screening marker for diagnosis and prostate cancer treatment are well known. The low specificity of PSA results in many unnecessary prostate biopsies, furthermore high rates of over-detection and overtreatment affect patients' quality of life. New assays measuring different molecular forms of PSA have resulted only in a moderate improvement of specificity especially beyond the PSA range of 2 to 10 ng/ml. Novel biomarkers for prostate cancer detection are emerging and they might enable clinicians to differentiate indolent from aggressive cancers in order to minimize overtreatment in future. (c) 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
biomarkers, prostate cancer detection, PSA, screening
in
European Urology. Supplement
volume
7
issue
5
pages
393 - 395
publisher
Elsevier
external identifiers
  • wos:000254671100001
  • scopus:44549087693
ISSN
1569-9056
DOI
10.1016/j.eursup.2008.01.018
language
English
LU publication?
yes
id
92f963bf-5e95-4bc2-a120-f02e4e098cfe (old id 1207505)
date added to LUP
2008-08-27 13:22:50
date last changed
2017-01-01 06:21:55
@article{92f963bf-5e95-4bc2-a120-f02e4e098cfe,
  abstract     = {The limitations of PSA as a screening marker for diagnosis and prostate cancer treatment are well known. The low specificity of PSA results in many unnecessary prostate biopsies, furthermore high rates of over-detection and overtreatment affect patients' quality of life. New assays measuring different molecular forms of PSA have resulted only in a moderate improvement of specificity especially beyond the PSA range of 2 to 10 ng/ml. Novel biomarkers for prostate cancer detection are emerging and they might enable clinicians to differentiate indolent from aggressive cancers in order to minimize overtreatment in future. (c) 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved.},
  author       = {Abrahamsson, Per-Anders and Tinzi, Martina},
  issn         = {1569-9056},
  keyword      = {biomarkers,prostate cancer detection,PSA,screening},
  language     = {eng},
  number       = {5},
  pages        = {393--395},
  publisher    = {Elsevier},
  series       = {European Urology. Supplement},
  title        = {Do we need PSA and early detection of prostate cancer?},
  url          = {http://dx.doi.org/10.1016/j.eursup.2008.01.018},
  volume       = {7},
  year         = {2008},
}